Pharmacoeconomic review report Savuconazole (Cresemba) (AVIR pharma inc.) / CADTH Canadian Drug Expert Committee.

Format:

Book

Author/Creator:

CADTH Canadian Drug Expert Committee, author, issuing body.

Language:

English

Subjects (All):

Antifungal agents.

Outcome assessment (Medical care).

Physical Description:

1 online resource (38 pages)

Place of Publication:

Ottawa (ON) : CADTH, 2019.

Summary:

Isavuconazole (Cresemba) is an azole antifungal drug indicated for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in adults. It is available in powder form for intravenous (IV) administration and in capsule form for oral use. A vial for IV administration contains 200 mg of isavuconazole, priced at 400, while an oral capsule contains 100 mg of isavuconazole, priced at 78.83. Treatment is initiated with a loading dose of 200 mg every eight hours for six doses (48 hours) followed by a maintenance dose of 200 mg daily. Clinical experts recommend a minimum of 6 to 12 weeks of treatment for IA, while achieving a favourable clinical response in IM will take several weeks. At the manufacturer's submitted price, the daily cost for the loading dose is 472.98 for the oral formulation and 1,200 for the IV formulation. The daily cost for the maintenance dose is 157.66 for the oral formulation and 400 for the IV formulation. Based on CADTH's calculations, an eight-week treatment course will cost 9,460 using the oral formulation and 24,000 using the IV formulation. The manufacturer submitted a cost-utility analysis comparing isavuconazole with voriconazole in patients with suspected IA.

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's PE Submission

Manufacturer's Base Case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Summary of Key Outcomes

Appendix 3. Additional Information

Appendix 4. Summary of Other HTA Reviews of Drug

Appendix 5. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.